PHI FPX 3200 assessment 2

PHI FPX 3200 Assessment 2 A Right to Experimental Drugs? 

A Right to Experimental Drugs 

Rhetoric of right to experimental drugs is controversial, and it has generated fierce debate on both sides. It is claimed that access to experimental drugs is providing hope and potential cure to those who are beyond traditional treatments. Arguments against it are based on safety, effectiveness, and ethics of using untested treatment with unknown determination (Bunnik, 2019). Painstaking risk and reward balancing of experimental drugs should be appreciated in this argument. Informed consent is required, with the patients having to be apprised of the possible risks, rewards, and unknowns of such treatment. Regulatory bodies such as the Federal Drug Administration (FDA) have a key role to play in making inferences concerning the safety and effectiveness of treatments (FDA, 2019). Its supporters insist that over-prudence will close the door of lifesaving medicine to patients, but others’ opinion is such that regulatory powers are necessary if patient protection can be provided. Whether or not there is any right to experimental drugs is something of complexity in need of diligent analysis and consideration of the involved ethical issues. 

 Ethical Theories and Moral Principles 

Ethical theories and moral principles significantly influence decision-making and ethical resolution of healthcare problems. Grounded ethical theories such as utilitarianism, deontological ethics, and virtue ethics, and moral principles such as autonomy, beneficence, non-maleficence, and justice influence ethical deliberation in healthcare (Mathúna et al., 2020; Vearrier & Henderson, 2021). These paradigms inform solutions to pressing challenges to healthcare, including problems like the use of experimental drugs, end-of-life care, medical confidentiality, and informed consent. Utilitarianism would balance probable goods against evils in experimental drug administration, for example, while deontological ethics would consider obligations toward securing patients’ safety and their autonomy (Tseng & Wang, 2021). Virtue ethics can prioritize building empathetic decision-making. Blending these theories of morality and ethical principles in healthcare decision-making requires an approach to ethics that is holistic.

Principle of Informed Consent

Informed consent is of primary importance when trial drugs are used, considering they are under testing continuously and not usually approved. Informed consent is essentially providing prior notification to patients or volunteers of possible risks and benefits of medical interventions or studies before their registration (Dankar et al., 2019). In experimental treatment, informed consent is especially important as participants are put at higher risk than in the case of authorized treatments. Clinical trial participants should be thoroughly informed about the nature of the drug, its possible benefits, risks, such as side effects, and other treatments. Furthermore, assessment of participants’ cognitive knowledge of information provided and voluntary, uncoerced participation is important (Varkey, 2021). Essentially, informed consent protects patient autonomy respect and enables patient informed decision-making in research. 

Assumptions 

Informed consent on experimental drug trials is based on a number of fundamental assumptions such as respect for the autonomy of patients, full disclosure of facts, comprehension by the patient, voluntariness, and continuous consent. Such assumptions maintain patients’ respect and dignity values and protect their capacity to make an educated decision about their health.

 Costs and Benefits of Unapproved Experimental Drugs

The reasoning behind access by patients of unauthorized experimental medication is not simple with good reasoning available on either side.

Those supporting it argue that it allows promising life-saving therapies, spurs innovation, and provides access to life-enhancing therapies (Feustel et al., 2019).

But the search comes at its own risks.

Off-label medication is not subjected to stringent trials and can have hidden, perhaps harmful, side effects. Apart from that, their effectiveness is yet to be established, bringing ineffectual treatment. Ethical requirements of risk-benefit assessment and informed consent also increase the issue’s complexity (Madeddu et al., 2021). Stakeholders need to handle such complexities with caution, weighing likely benefits against patient safety risk without compromising ethical principles. 

Pre-approved Drug Usage for a Wider Patient Pool 

Expanding the Use of Pre-Approved Drugs for More Patient Groups Widening the application of pre-approved drugs to more patients generates a mixed response. It can improve patient outcomes and extend therapy coverage, as well as lowering healthcare costs, according to one line of argument (White, 2022). The second advocates avoidance of over-drugging and observance of respect for individualized treatment based on individual patient need (Heydari et al., 2020). The patient’s autonomy and the duty of caring for the patient above anything else are principles of morality invoked by the demand for a balanced method to practice (Borysowski & Górski, 2019).

 Knowledge Gaps and Missing Information 

Completing gaps in knowledge and filling gaps in information is important in the acquisition of knowledge and decision-making about off-label prescription of drugs. There is information to be gathered for determining the safety, efficacy, and ethics pertaining to the widening of approved drugs. Evidence-based studies in the context of long-term effects, ethics, and risk patient populations also have to be conducted (Cohen et al., 2020). Obtaining correct information and further research are all needed only to enable informed decision-making in the scenario. 

Conclusion 

Generally, the problem here with experimental drugs is one of finding balance between ethical concerns and moral beliefs. As wonderful as experimental drugs promise good, they are used with risk as well as ethical issues.

Finding a balance between potential benefits and safety for patients is crucial, and regulatory agencies play a crucial role in ensuring compliance with ethics.

Lastly, experimental treatment options need to be determined in light of patient interests after careful risk-benefit analysis and ethics.

PHI FPX 3200 Assessment 2 A Right to Experimental Drugs? 

Heydari, M., Mehraeen, M., & Joulaei, H. (2020). Overmedication and waste of resources in physicians’ prescriptions: A cross-sectional study in southwestern Iran. Shiraz E-Medical Journal, 21(9). https://doi.org/10.5812/semj.97662 Madeddu, C., Neri, M., Oppi, S., Sanna, E., & Macciò, A. (2021). Experimental drugs for chemotherapy- and cancer-related anemia. Journal of Experimental Pharmacology, Volume 13, 593–611. https://doi.org/10.2147/jep.s262349 Nandifa, V. N., Jena, Y., & Joewana, S. Beneficence is the highest moral imperative of a doctor dealing with the poor quality of patient autonomy. Jurnal Pendidikan Kedokteran Indonesia: The Indonesian Journal of Medical Education, 9(1), 44. https://doi.org/10.22146/jpki.44511 O’Mathúna, D. P., Escartín, C. P., Roche, P., & Marlowe, J. (2020). Engaging citizen translators in disasters. Translation and Interpreting Studies. https://doi.org/10.1075/tis.20003.oma Quaranta, A., D’Isidoro, O., Piattelli, A., Hui, W. L., & Perrotti, V. (2022). Illicit drugs and periodontal diseases. Periodontology 2000, 90(1), 62–87. https://doi.org/10.1111/prd.12450

PHI FPX 3200 Assessment 2 A Right to Experimental Drugs

Tseng, P.-E., & Wang, Y.-H. (2021). Deontological or utilitarian? An eternal ethical dilemma in outbreak. International Journal of Environmental Research and Public Health, 18(16), 8565. https://doi.org/10.3390/ijerph18168565 Varkey, B. (2021). Principles of clinical ethics and their application to practice. Medical Principles and Practice, 30(1), 17–28. https://doi.org/10.1159/000509119 Vearrier, L., & Henderson, C. M. (2021). Utilitarian principlism as a framework for crisis healthcare ethics. HEC Forum, 33(1), 45–60. https://doi.org/10.1007/s10730-020-09431-7 White, C. M. (2022). Ongoing threat of food contaminated with approved and unapproved medications as dietary supplements: Evaluation of the US Food and drug administration’s contaminated supplements database 2007-2021. The Journal of Clinical Pharmacology, 62(8), 928–934. https://doi.org/10.1002/jcph.2046